anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide an antitumor agent containing heptelidic acid chlorohydrin, having high antitumor activity and exhibiting selective cytotoxic action on human tumor cell. CONSTITUTION:This antitumor agent contains the compound of formula or its salt and a pharmacologically permissible carrier as active components. It can be prepared in the form of oral administration agent or parenteral administration agent by conventional method and is administered at a daily rate of 0.01-10mg/kg for parenteral administration and 0.5-20mg/kg for oral administration. The compound of formula can be produced by culturing Acremonium sp. No.618 (a microbial strain belonging to the genus Acremonium and capable of producing heptelidic acid chlorohydrin) in a medium and separating the heptelidic acid chlorohydrin produced and accumulated in the cultured product. The agent exhibits high injuring action exclusively on tumor cells at a low concentration compared with conventional chemotherapeutic agent.
Deliberate or accidental overdosage of oral disopyramide may be followed by apnea, loss of consciousness, cardiac arrhythmias, and loss of spontaneous respiration. Death has occurred following overdosage.

Toxic plasma levels of disopyramide produce excessive widening of the QRS complex and Q-T interval, worsening of congestive heart failure, hypotension, varying kinds and degrees of conduction disturbance, bradycardia, and finally asystole. Obvious anticholinergic effects are also observed.

The approximate oral LD of disopyramide phosphate is 580 and 700 mg/kg for rats and mice, respectively. 50
Standard x-ray on all operated patients was taken pre- and postoperative and at 3 and 12 moths. Including an AP pelvis and lateral view of the hip.
A care system includes a mobile communication device, a remote server, and a patient support system in communication with either or both of the mobile communication device and the remote server. The mobile communication device operates as a user interface for the patient support system. The remote server provides computing power for the patient support system for resource intensive computing tasks. A system for use in a healthcare facility includes patient care devices located in a patient room. The system also includes an application server located remotely from the patient room. The application server stores application software associated with each patient care device. The system further includes a universal caregiver interface situated in the patient room and in communication with the application server. The universal caregiver interface receives application software from the application server. The universal caregiver interface is then usable to control the operation of each of the plurality of patient care devices in accordance with the application software.
After approval from the hospital's institutional review board, a prospective clinical study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH \& RC), Lahore, from January 25, 2021 to July 25, 2021. Data was collected from 60 patients that fulfilled the inclusion criteria. Features considered, included patients' demographic including age, gender, co-morbidities and American Society of Anesthesiologist physical status. In addition mallampati score, mouth opening and Wilson score of all patients was recorded as part of routine anesthesia airway assessment. Patients being taken for study were randomly assigned to either of the two groups of 30 each, that is all patients at odd numbers (1, 3, 7, 9 etc.) was allocated to Group 1 (McGrath laryngoscope) whereas all patient at even numbers (2, 6, 8, 10 etc.) was allocated to Group 2 (Macintosh laryngoscope). After explaining the procedure in detail and obtaining an informed consent in the presence of a witness, patients were transferred to the operating room. After standard induction of anesthesia, tracheal intubation using either of the two laryngoscopes depending on group allocation (McGrath laryngoscope or Macintosh laryngoscope) was performed by a designated anesthesia consultant experienced in the use of double-lumen tubes. The requirement of external laryngeal manipulation was recorded on a predesigned checklist.
Parkinson's disease (PD) is a neurodegenerative disorder of the dopamine-producing nerve cells in the basal ganglia, and age is a primary risk factor for PD. Cognitive impairment is prevalent, disabling, and poorly managed among the 1 million adults living with PD in the United States. Indeed, cognitive impairment begins early in PD, and dementia develops in 80% of persons with PD. Cognitive impairment is further associated with worse fatigue, depression, anxiety, pain, and quality of life (QOL) in PD. Those observations underscore the importance of identifying efficacious approaches for managing cognitive impairment and its consequences, and promoting additional health benefits among those with PD. To date, researchers have examined the benefits of supervised, structured exercise training for managing outcomes of PD, but this approach has clear barriers associated with travel, transportation, and participation (i.e., loss of driving ability, social isolation, and lack of community integration) that are common in PD. The investigators believe that there is merit in the promotion of physical activity for managing cognitive dysfunction and other symptom and QOL outcomes in PD. The investigators offer a novel and innovative approach for promotion of physical activity in PD based on their extensive experiences from Phase I, II, and III randomized controlled trials (RCTs). Those RCTs indicate that the remotely-delivered, social-cognitive theory-based behavioral intervention has successfully increased self-reported and device-measured physical activity in persons with multiple sclerosis (MS). This approach has further resulted in improvements in cognition and walking outcomes, symptoms of fatigue, depression, anxiety, and pain, and QOL among persons with MS. The investigators leverage their experiences and preliminary results in MS, and propose a Stage-I RCT that examines the feasibility and efficacy of a remotely-delivered, theory-based behavioral intervention focusing on combined exercise (aerobic and resistance) training for yielding immediate improvements in device-measured physical activity (primary outcome) among persons with PD who are physically inactive. The investigators further examine the efficacy of this behavioral intervention for improvements in cognitive function, symptoms, and QOL (secondary outcomes). The proposed study, if successful, will provide experiences and pilot data necessary for the design of a subsequent Stage-II RCT that examines the efficacy of the behavioral intervention for immediate and sustained improvements of outcomes in an appropriately-powered and clearly-demarcated sample of adults with PD (i.e., those 50+ years of age who are prescreened for cognitive impairment). This line of research may yield "real-world" guidelines for physical activity that can be implemented for the treatment of cognitive dysfunction and other outcomes in PD. Such an opportunity for rehabilitation of cognitive function using an approach with broad reach and scalability is paramount considering the prevalent, disabling, and poorly managed nature of cognitive impairment in PD and limited efficacious resources for its treatment.
This group will receive nutrition education during the first week of the study. This group will perform a minimum of 150 minutes of moderate exercise each week and must be spread out in at least 2 days.
The Solve-RD project brings together clinicians, scientists, and patient representatives from 51 institutes spanning 15 countries to collaborate on genetically diagnosing ("solving") rare diseases (RDs). The project aims to significantly increase the diagnostic success rate by co-analyzing data from thousands of RD cases, including phenotypes, pedigrees, exome/genome sequencing, and multiomics data. Here we report on the data infrastructure devised and created to support this co-analysis. This infrastructure enables users to store, find, connect, and analyze data and metadata in a collaborative manner. Pseudonymized phenotypic and raw experimental data are submitted to the RD-Connect Genome-Phenome Analysis Platform and processed through standardized pipelines. Resulting files and novel produced omics data are sent to the European Genome-Phenome Archive, which adds unique file identifiers and provides long-term storage and controlled access services. MOLGENIS "RD3" and Café Variome "Discovery Nexus" connect data and metadata and offer discovery services, and secure cloud-based "Sandboxes" support multiparty data analysis. This successfully deployed and useful infrastructure design provides a blueprint for other projects that need to analyze large amounts of heterogeneous data.
Up to six adult subjects are planned for the Phase I portion of this study. Subjects are enrolled upon obtaining consent and meeting entry criteria. This study is an intra-patient comparison of KB105 and placebo-administered Target Areas. Patients will be evaluated for safety, and Target Areas will be assessed individually with the IGA and VIIS scales. Target Areas will be imaged and evaluated for safety and efficacy. Subjects will be on-trial for approximately 3.5 months.
Cases of basal cell carcinoma and other skin malignancies have been reported in patients treated with S1P receptor modulators, including PONVORY. In Study 1, the incidence of basal cell carcinoma was 0.4% in PONVORY-treated patients compared to 0.2% in patients receiving teriflunomide 14 mg. Cases of other cutaneous malignancies, including melanoma and squamous cell carcinoma, have also been reported in patients treated with PONVORY and in patients treated with other S1P modulators.

Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. Providers and patients are advised to monitor for suspicious skin lesions. If a suspicious skin lesion is observed, it should be promptly evaluated. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. Concomitant phototherapy with UV-B radiation or PUVA-photochemotherapy is not recommended in patients taking PONVORY.
A cross sectional study (survey) will be conducted among dental students in faculty of dentistry Cairo University for the duration of one month from June 2020 to July 2020.

The questionnaire has three parts. The first part included demographic details. The second part included validated general anxiety disorder scale GAD-7. Questionnaire consisting of seven questions which measures students' anxiety level score. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. The third part the validated self administered, structured, and close ended 15 questions that assessed the self reported oral hygiene practices 11. The questionnaire forms were kept anonymous. The questionnaire was validated.
Despite a remarkable reduction in global poverty and famines, substantial childhood malnutrition continues to persist. In 2017, over 50 million and 150 million young children suffered from acute malnutrition (wasting) and chronic malnutrition (stunting), respectively. Yet, the measurable impact of determinants is obscure. We evaluate proposed socio-environmental related determinants of stunting and wasting across Kenya and Nigeria and quantify their effectiveness. We combine health and demographic data from Kenya and Nigeria Demographic Health Surveys (2003, 2008-2009, 2013, 2014) with spatially explicit precipitation, temperature, and vegetation data. Geospatial and disaggregated data help to understand better who is at risk and where to target mitigation efforts. We evaluate the responsiveness of malnutrition indicators using a four-level random intercept hierarchical generalized logit model. We find that spatial and hierarchical relationships explain 28% to 36% of malnutrition outcome variation. Temporal variation in precipitation, temperature, and vegetation corresponds with more than a 50% change in malnutrition rates. Wasting is most impacted by mother's education, family wealth, clinical delivery, and vaccinations. Stunting is most impacted by family wealth, mother's education, clinical delivery, vaccinations, and children asymptomatic of fever, cough, or diarrhea. Remotely monitored climatic variables are powerful determinants, however, their effects are inconsistent across different indicators and locations.
PCT No. PCT/FR96/01925 Sec. 371 Date Jun. 8, 1998 Sec. 102(e) Date Jun. 8, 1998 PCT Filed Dec. 4, 1996 PCT Pub. No. WO97/20572 PCT Pub. Date Jun. 12, 1997Polar lipid composition of plant origin for conveying an active agent and/or making it penetrate into a target cell, the composition being characterized in that it is comprised of an injectable, intra-articular, topical or ingestable aqueous emulsion of a polar lipid mixture rich in phospholipids, in glycolipids and in ceramides, having a composition which is substantially similar to that of the polar lipids constituents of lipid cytomembranes of cells and obtained from a plant compound such as cereal flour or an extract such as bran or lipids extracted from cereals by means of chlorinated solvants.
BACKGROUND: The impact of hepatic resection type on long-term oncological prognosis of patients with early-stage hepatocellular carcinoma (HCC) has not been systematically investigated. We sought to determine risk factors, recurrence patterns, and survival outcomes after anatomical resection (AR) versus non-anatomical resection (NAR) for early-stage HCC.
METHODS: From a prospectively collected multicenter database, consecutive patients undergoing curative hepatectomy for early-stage HCC were identified. Recurrence patterns, overall survival (OS), recurrence-free survival (RFS), and risk factors were investigated in patients undergoing AR versus NAR using propensity score matching (PSM), subgroup analysis, and COX regression analysis.
RESULTS: A total of 3585 patients with early-stage HCC were enrolled, including 1287 and 2298 in the AR and NAR groups, respectively. After PSM, the OS and RFS of patients in the AR group were 58.8% and 42.7%, which were higher than those in the NAR group (52.2% and 30.6%, both p < 0.01). The benefits of AR were consistent across most subgroup analyses of OS and RFS. Multivariable COX regression analysis showed that AR was independently associated with better OS and RFS. Notably, although recurrence patterns were comparable, the risk factors for recurrence were not identical for AR versus NAR. Microvascular invasion and narrow resection margin were only associated with a higher recurrence rate after NAR.
CONCLUSIONS: This study demonstrated that AR decreases the risk of tumor recurrence and improves OS and RFS in patients with early-stage HCC. AR should be adopted as long as such a surgical maneuver is feasible for initial treatment of early-stage HCC.
The patient was a 38-year-old man who was admitted to our hospital with fever, vomiting and unclear speech. Blood tests showed hemolytic anemia, thrombocytopenia, and elevated creatinine, and a Coombs test was negative. ADAMTS13 activity was <1% and ADAMTS13 inhibitor was 0.7 BU/ml, so we diagnosed acquired thrombotic thrombocytopenic purpura (aTTP). We started plasma exchange and prednisolone 1 mg/kg on the day of admission (day 1). The platelet count recovered to normal on day 5, and hemolytic findings improved. However, symptoms worsened again, and thus we started rituximab for refractory aTTP on day 24. After rituximab administration, the patient showed no signs of infusion reaction (IR) or recurrence. On day 31, he received the second dose of rituximab and was discharged. On day 38, he had knee pain, fever, erythema, and difficulty moving. CRP was elevated and CH50 slightly decreased. Imaging findings were normal. Anti-rituximab antibody was positive (197 ng/ml), leading to the diagnosis of rituximab-induced serum sickness. Rituximab administration was discontinued, and the serum sickness has not recurred. The presence of anti-rituximab antibodies may aid diagnosis in patients with suspected symptoms of serum sickness or recurring IR-like symptoms.
The present invention discloses novel smooth muscle cell specific promoters and uses thereof. The promoters are suited for providing nucleic acid of interest with the capability of expressing specifically in a contractile smooth muscle cell, preferably a vascular contractile smooth muscle cell and/or a visceral contractile smooth muscle cell. One example of such a promoter is a smoothelin gene promoter. For gene therapy purposes said smoothelin gene promoter is preferably derived from a human. A promoter of the invention may be incorporated into nucleic acid delivery vehicle. The nucleic acid delivery vehicle preferably comprises a virus-like particle such as an adenovirus particle, an adeno-associated virus particle or a retrovirus particle.
BACKGROUND: Polypharmacy and opioid administration are thought to increase the risk of postoperative cognitive dysfunction and delirium in elderly patients. Spinal anesthesia (SA) holds potential to reduce perioperative polypharmacy in spine surgery. As more geriatric patients undergo spine surgery, understanding how SA can reduce polypharmacy and opioid administration is warranted. We aim to compare the perioperative polypharmacy and dose of administered opioids in patients ≥65 years who undergo transforaminal lumbar interbody fusion (TLIF) under SA versus general anesthesia (GA).
METHODS: A retrospective analysis of 200 patients receiving a single-surgeon TLIF procedure at a single academic center (2014-2021) was performed. Patients underwent the procedure with SA (n = 120) or GA (n = 80). Demographic, procedural, and medication data were extracted from the medical record. Opioid consumption was quantified as morphine milligram equivalents (MME). Statistical analyses included χ2 or Student's t-test.
RESULTS: Patients receiving SA were administered 7.45 medications on average versus 12.7 for GA patients (P < 0.001). Average perioperative opioid consumption was 5.17 MME and 20.2 MME in SA and GA patients, respectively (P < 0.001). The number of patients receiving antiemetics and opioids remained comparable postoperatively, with a mean of 32.2 MME in the GA group versus 27.5 MME in the SA group (P = 0.14). Antiemetics were administered less often as a prophylactic in the SA group (32%) versus 86% in the GA group (P < 0.001).
CONCLUSIONS: SA reduces perioperative polypharmacy in patients ≥65 years undergoing TLIF procedures. Further research is necessary to determine if this reduction correlates to a decrease the incidence of postoperative cognitive dysfunction and delirium.
Provided herein are a composite of photosensitizer-metal nanoparticles and a composition for photodynamic therapy or diagnosis comprising the same. The composite of the present invention is comprised of a photosensitizer; metal nanoparticles; and backbones which connect the photosensitizer with the metal nanoparticles. The backbones comprise polypeptide substrates which can be specifically degraded by protease. The composite inhibits fluorogenesis and generation of reactive oxygen species in normal tissues, whereas fluorogenesis and generation of reactive oxygen species are activated in neoplastic tissues. The composite can thus effectively destroy neoplastic tissues. Also, the selective fluorogenesis in neoplastic tissues allows the accuracy of detection of neoplasms using the composite to be enhanced.
The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent overdose [see Dosage and Administration (2.10)].

When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.

If local injection site reactions occur following VELCADE administration subcutaneously, a less concentrated VELCADE solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously [see Dosage and Administration (2.10)]. Alternatively, consider use of the intravenous route of administration  [see Dosage and Administration (2.10)].

VELCADE is a hazardous drug. Follow applicable special handling and disposal procedures.1
PURPOSE: To investigate the impact of preoperative compensatory curve on the postoperative curve progression in congenital scoliosis (CS) patients following thoracolumbar hemivertebra (HV) resection and short fusion.
METHODS: This study retrospectively reviewed a consecutive cohort of patients with CS who underwent thoracolumbar HV resection and short fusion with a minimum of 2 years follow-up. According to the preoperative curve pattern, patients were divided into compensatory curve group non-compensatory curve group. Based on the postoperative coronal curve evolution, patients were further divided into the progressed group (Group P, with curve decompensation ≥ 20°) and the non-progressed group (Group NP, characterized by well-compensated curves).
RESULTS: A total of 127 patients were included in this study, with 31 patients in the compensatory curve group and 96 patients in the non-compensatory curve group. The incidence of postoperative coronal curve progression was significantly higher in the compensatory curve group than that in non-compensatory curve group (35.5% vs. 13.5%, p = 0.007). In the compensatory curve group, patients who experienced postoperative curve progression showed fewer fusion segments (p = 0.001), greater preoperative UIV translation (p = 0.006), greater preoperative LIV tilt (p = 0.017), and larger postoperative UIV tilt (p < 0.001) compared with patients in group NP. Multiple logistic regression demonstrated that the shorter fusion segments and greater postoperative UIV tilt were two independent risk factors for postoperative curve progression.
CONCLUSION: The presence of the compensatory curve was associated with a higher incidence of postoperative curve progression in patients with CS who underwent thoracolumbar HV resection and short fusion. Shorter fusion segments and greater postoperative UIV tilt were found to be the risk factors for postoperative curve progression.